SITE005-0074

SITE005 (FRA) › SITE005-0074

SITE005-0074

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2025-11-17

enrolled

AEs

2

Serious

0

Dropout signal

–

Adverse events

2

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-12-29 (study day 212); relationship: not assessed

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-08-27 (study day 88); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.